149 related articles for article (PubMed ID: 33247459)
1. The incidence of post-transplant malignancies in kidney transplant recipients treated with Rituximab.
Bachelet T; Visentin J; Davis P; Taton B; Guidicelli G; Kaminski H; Merville P; Couzi L
Clin Transplant; 2021 Feb; 35(2):e14171. PubMed ID: 33247459
[TBL] [Abstract][Full Text] [Related]
2. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
4. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
5. Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab.
Pham C; Kuten SA; Knight RJ; Nguyen DT; Graviss EA; Gaber AO
Transpl Infect Dis; 2020 Jun; 22(3):e13257. PubMed ID: 32031729
[TBL] [Abstract][Full Text] [Related]
6. Additional Benefits of Rituximab and Plasma Exchange on Top of Standard Induction Therapy in Kidney Transplant Recipients With a Negative CDC Crossmatch but High Preformed Donor Specific Antibody Titer.
Mohamadou I; Matignon M; Malard S; Lombardi Y; Buob D; Moktefi A; Jamme M; Ouali N; Rafat C; François H; Petit-Hoang C; Rondeau E; Mesnard L; Grimbert P; Taupin JL; Luque Y
Transpl Int; 2023; 36():10844. PubMed ID: 37056357
[TBL] [Abstract][Full Text] [Related]
7. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
[TBL] [Abstract][Full Text] [Related]
8. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
[TBL] [Abstract][Full Text] [Related]
9. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia.
Jalalonmuhali M; Ng KP; Mohd Shariff NH; Lee YW; Wong AH; Gan CC; Lim SK
Transplant Proc; 2020; 52(6):1718-1722. PubMed ID: 32448671
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
11. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
[TBL] [Abstract][Full Text] [Related]
12. The impact of induction therapy in low-immunological risk kidney transplant recipients regardless of HLA matching.
Abou-Jaoudé M; Akiki D; Moussawi A; Abou-Jaoudé W
Transpl Immunol; 2023 Feb; 76():101773. PubMed ID: 36526105
[TBL] [Abstract][Full Text] [Related]
13. Non-melanoma skin cancer in Portuguese kidney transplant recipients - incidence and risk factors.
Pinho A; Gouveia M; Cardoso JC; Xavier MM; Vieira R; Alves R
An Bras Dermatol; 2016; 91(4):455-62. PubMed ID: 27579740
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S
Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361
[TBL] [Abstract][Full Text] [Related]
15. [Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients].
Fang JL; Chen Z; Guo YH; Ma JJ; Pan GH; Li GH; Xu L; Zhang L; Lai XX; Yin W; Yao ZP; Chen LB
Zhonghua Yi Xue Za Zhi; 2019 Apr; 99(16):1232-1236. PubMed ID: 31060162
[No Abstract] [Full Text] [Related]
16. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
[TBL] [Abstract][Full Text] [Related]
17. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
18. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
19. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
20. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
